Forward-Looking Statements
This press release contains forward-looking statements based on Silicon Labs' current expectations. The words "believe", "estimate", "expect", "intend", "anticipate", "plan", "project", "will", and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Silicon Labs and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment, including disruptions in the financial services industry; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs' business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; risks that demand and the supply chain may be adversely affected by military conflict (including between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally (including conflict between Taiwan and China); risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs' distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility the impact of COVID-19 on the U.S. and global economy; debt-related risks; capital-raising risks; the timing and scope of share repurchases and/or dividends; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs' products and its networks and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. References in this press release to Silicon Labs shall mean Silicon Laboratories Inc.
Note to editors: Silicon Laboratories, Silicon Labs, the "S" symbol, and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.
Silicon Laboratories Inc. | |||
Condensed Consolidated Statements of Income | |||
(In thousands, except per share data) | |||
(Unaudited) | |||
| |||
| Three Months Ended | ||
| April 1, 2023 |
| April 2, 2022 |
Revenues | $246,787 |
| $233,814 |
Cost of revenues | 92,927 |
| 78,042 |
Gross profit | 153,860 |
| 155,772 |
Operating expenses: |
|
|
|
Research and development | 89,396 |
| 77,542 |
Selling, general and administrative | 44,891 |
| 44,647 |
Operating expenses | 134,287 |
| 122,189 |
Operating income | 19,573 |
| 33,583 |
Other income (expense): |
|
|
|
Interest income and other, net | 4,836 |
| 1,499 |
Interest expense | (1,656) |
| (1,680) |
Income before income taxes | 22,753 |
| 33,402 |
Provision for income taxes | 7,753 |
| 11,689 |
Equity-method earnings (loss) | (1,033) |
| 1,194 |
Net income | $ 13,967 |
| $ 22,907 |
|
|
|
|
Earnings per share: |
|
|
|
Basic | $ 0.44 |
| $ 0.60 |
Diluted | $ 0.41 |
| $ 0.58 |
|
|
|
|
Weighted-average common shares outstanding: |
|
|
|
Basic | 31,959 |
| 38,003 |
Diluted | 33,753 |
| 39,523 |
Non-GAAP Financial Measurements